Perfusion CT Scans for Kidney Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether a special type of CT scan, called dynamic contrast enhanced CT (DCE-CT), can determine the effectiveness of certain kidney cancer treatments. It is part of a larger study where patients receive one of three study drugs: everolimus, bevacizumab, or pazopanib, all targeting advanced kidney cancer. Suitable candidates for this trial have metastatic renal cell carcinoma (kidney cancer that has spread) and are either already participating in or considering the related study. The trial involves scanning before and after treatment to assess cancer response. As a Phase 3 trial, this study represents the final step before FDA approval, offering patients a chance to contribute to potentially groundbreaking treatment advancements.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that perfusion CT scans are safe for kidney cancer patients?
Research has shown that perfusion CT scans, which use a special imaging technique with a contrast dye, are generally safe for most people. Studies have found that the risk of kidney damage from the dye is low, particularly when kidney function, measured by creatinine levels, is normal.
For individuals with normal kidney function, the likelihood of sudden kidney damage from the dye is similar to those who don't receive it. However, about 11% of sudden kidney damage cases from medical procedures involve this type of dye. This indicates that while most people handle the procedure well, a small risk remains.
Prospective trial participants considering perfusion CT scans should understand these facts to weigh the benefits and risks. Discuss any concerns with a healthcare provider, especially if existing kidney issues are present.12345Why are researchers excited about this trial?
Researchers are excited about using perfusion CT scans for kidney cancer because these scans can provide a detailed picture of blood flow in tumors. Unlike standard imaging options, which typically focus on the size and shape of tumors, perfusion CT scans offer insights into how well blood is reaching the tumor tissue. This information could help doctors determine how a tumor is responding to treatment much earlier than traditional methods. By potentially predicting treatment success or failure sooner, this approach could lead to more personalized and effective treatment plans for patients with kidney cancer.
What evidence suggests that DCE-CT scans are effective for assessing kidney cancer treatment?
Research has shown that a special type of CT scan, called a dynamic contrast-enhanced CT (DCE-CT) scan, can detect changes in blood flow in kidney tumors. These changes are important because they can indicate if a treatment is effective. Studies have found that DCE-CT scans can predict long-term outcomes for patients with metastatic kidney cancer. In this trial, participants will undergo DCE-CT scans 4 weeks before and 8 weeks after starting treatment. The scans measure blood flow and volume in the tumor, which can signal how the cancer might respond to treatments like everolimus, bevacizumab, or pazopanib. Overall, DCE-CT is a promising tool for assessing the effectiveness of cancer treatments.46789
Who Is on the Research Team?
Chaan Ng, MD
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 with metastatic renal cell carcinoma who are enrolled or considering enrollment in the START trial. They must have good kidney function, not be pregnant or breastfeeding, and can't join if they've had recent radiotherapy to the tumor area or are allergic to CT contrast media.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-Treatment Assessment
DCE-CT scan performed to check the status of the disease before starting treatment on study 2010-0085
Treatment
Participants receive treatment as part of study 2010-0085 and undergo DCE-CT scan 8 weeks after starting treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Perfusion CT scan
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor